Solidus Investment

Dr.Diary is a company that specializes in developing a diabetes management application aimed at assisting users in monitoring and controlling their diabetes. Founded in 2017 and headquartered in Seoul, South Korea, the application allows users to track their blood glucose levels, record daily exercise routines, and receive reminders for medication intake. Additionally, it offers insights into how various foods affect blood sugar levels, thereby helping users make informed dietary choices. The platform includes features such as monthly health reports, daily tips for diabetes management, and communication tools that facilitate personal consultations with healthcare professionals. Through these services, Dr.Diary aims to empower individuals with diabetes to better manage their health and improve their quality of life.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

Novelty Nobility Inc. is a private biotech company dedicated to researching novel angiogenesis targets and developing antibody-based therapeutics, particularly in the fields of ophthalmology and oncology. The company has identified Stem Cell Factor (SCF) and c-KIT as significant angiogenesis targets, which are linked to the proliferation and survival of hematopoietic stem cells. By focusing on the anti-SCF/c-KIT pathway, Novelty Nobility aims to address the unmet medical needs associated with existing anti-VEGF treatments, specifically regarding efficacy and long-term safety. The company is actively engaged in developing therapeutic antibodies and antibody-drug conjugates to combat drug resistance and the negative effects of aberrant blood vessel growth in conditions such as retinal diseases and solid tumors. Their lead candidate, NN2101, a full-human monoclonal antibody, is currently in preclinical development and is supported by strong patent protection in the United States and South Korea.

Neurophet, Inc., founded in 2016 and based in Seoul, South Korea, is a neuroscience company that specializes in developing advanced simulation software for brain stimulation effects. Their flagship product, Neurophet tES Lab, utilizes individual brain structure data and stimulus conditions to calculate and visualize these effects. The company's technology, known as Segengine, automatically segments brain magnetic resonance images into 107 regions within a minute, enhancing the precision of their neuro-navigation tools. These solutions are designed to assist clinicians in treating patients with brain diseases, including Alzheimer's, by providing detailed three-dimensional brain models and stimulation parameter guidance through deep learning and numerical optimization techniques.

Optolane Technologies Inc. is a biotechnology company based in Seongnam, South Korea, founded in 2012. The company specializes in manufacturing portable photo sensor chip-based PCR machines for life science applications. It has developed a diagnostic platform that offers molecular and immunoassay point-of-care testing alternatives. Optolane's semiconductor-integrated in-vitro diagnostic devices focus on real-time and digital PCR, utilizing advanced optical and thermal control systems. By providing innovative diagnostic solutions, Optolane aims to facilitate disease diagnosis and enhance the quality of life for individuals.

Himedi, Inc. is a digital health platform based in Seoul, South Korea, that facilitates connections between international patients and medical service providers. Founded in 2011, the company offers a hospital reservation service and provides consultations with doctors, ensuring that patients receive personalized recommendations for clinics. Service managers accompany clients throughout their medical journey, enhancing the overall experience for medical tourists. Himedi aims to improve the quality of life for its users by offering comprehensive support during their treatment processes.

Orum Therapeutics, Inc. is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of a novel class of therapeutic antibodies through its proprietary cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's approach enables the intracellular delivery of active antibody therapeutics or payloads, allowing it to inhibit drug targets that are typically considered undruggable by existing small molecules or antibody treatments. The technology is adaptable, capable of targeting various cell types and intracellular proteins without the need for chemical modifications. By merging the precision of antibodies with the efficacy of protein degraders, Orum aims to facilitate the development of new medicines that can effectively treat patients with challenging health conditions.

Orum Therapeutics, Inc. is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of a novel class of therapeutic antibodies through its proprietary cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's approach enables the intracellular delivery of active antibody therapeutics or payloads, allowing it to inhibit drug targets that are typically considered undruggable by existing small molecules or antibody treatments. The technology is adaptable, capable of targeting various cell types and intracellular proteins without the need for chemical modifications. By merging the precision of antibodies with the efficacy of protein degraders, Orum aims to facilitate the development of new medicines that can effectively treat patients with challenging health conditions.

Vitrosys Inc. is a bio-engineering company based in Yeongju, South Korea, founded in 2002. The company specializes in the development and manufacturing of plant-based medicines, utilizing advanced biotechnological methods to create products from single cells and tissues. Vitrosys offers a diverse range of health-related products, including natural materials, bio reactors, and functional foods designed to promote health. Its product line features cultured roots of Korean mountain ginseng and various extracts, vials, and beverages derived from these roots. Additionally, Vitrosys provides research outsourcing and joint research services, aimed at supporting the industrialization of beneficial plant resources in strictly controlled facilities. The company's commitment to biopharmaceutical innovation enables the extraction and identification of natural metabolites with physiological benefits for human health.

Alteogen Inc. is a biotechnology company founded in 2008 and headquartered in Daejeon, South Korea. The company specializes in the development of next-generation biopharmaceuticals, including long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. Alteogen's innovative technologies include NexP Fusion Technology for long-acting biobetters and NexMab ADC Technology for antibody-drug conjugates. Its current pipeline features several candidates in various stages of clinical trials, such as ALT-P1, a long-acting human growth hormone in Phase IIa, and ALT-Q2, a long-acting coagulation factor VII for hemophilia. Additionally, the company is developing ALT-P7 for targeted breast and gastric cancer and ALT-Q5, an antibody-drug conjugate for ovarian cancer. Alteogen also collaborates with other pharmaceutical companies, including Kissei Pharmaceutical and Cristalia, to enhance its product offerings.

Novarex Co., Ltd., founded in 2008 and headquartered in Cheongju, South Korea, specializes in the development and production of health functional foods and raw materials. The company offers a diverse range of dietary supplements, including lactic acid bacteria, probiotics, omega-3 products, and vitamins and minerals. Novarex provides various formulations such as tablets, hard capsules, powders, gummy jellies, and stick jellies, catering to different health needs, including eye health, dietary management, and support for pregnant women and children. Formerly known as Health Science Co., Ltd., Novarex rebranded in November 2011 to reflect its commitment to health and nutrition on both domestic and international markets.

BioLeaders Corporation is a healthcare company based in Yongin, South Korea, founded in 1999. The company focuses on developing innovative medicines, particularly in the field of oncology, with its flagship product being P53, an anti-cancer drug. BioLeaders is advancing several pipeline products, including BLS-H01, currently in phase 3 clinical trials for cervical cancer, and BLS-M07, which has completed phase 2b trials for the same condition. Additionally, the company is working on BLS-M22 for the treatment of Duchenne muscular dystrophy and BLC-H03, a vaccine adjuvant. Beyond pharmaceuticals, BioLeaders also offers health functional foods, raw materials, and functional cosmetic ingredients, positioning itself as a comprehensive provider in the healthcare sector.

Maniker F&G Co., Ltd. is a South Korean company specializing in the production, processing, and sale of frozen, chilled, and retorted food products. Founded in 1993 and headquartered in Yongin, the company offers a diverse range of meat products, including chicken and beef items, aimed at both home and business consumers. Notable offerings include Ginseng chicken stew, Mung bean chicken stew, Premium Samgyetang, boneless chicken tender, and Maniker popcorn chicken. Maniker F&G is also involved in exporting its products to the United States, emphasizing a commitment to providing delicious and safe food options through advanced meat processing technology and continuous innovation.